Beam provided updates on their third quarter 2024 business, highlighting data on BEAM-101 for sickle cell disease and ESCAPE technology for gene editing. They are optimistic about the potential impact of their therapies. BEAM-101 clinical data show promising results similar to sickle cell trait.